Alzamend Neuro, Inc. Common Stock (ALZN) Stock Price

ALZNStock
$1.6631.69%52W
Market Cap$8.01M
P/E
PEG Ratio
Div yield
Beta0.34

ALZN Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-32.50%
Price vs S&P 500 (4W)22.34%
VGM Score61.84

ALZN Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q1 2026-$0.67-$0.74-10.45%(-$0.07)
Q4 2025-$0.53-$0.58-9.43%(-$0.05)
Q3 2025-$1.96-$0.30+84.65%(+$1.66)
Q2 2025-$0.69-$1.28-85.51%(-$0.59)
Q1 2025-$2.70-$9.48-251.11%(-$6.78)

ALZN Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.14
4.14
4.14

Industry Peers — Pharmaceuticals(570)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
ALZNAlzamend Neuro, Inc. Common Stock
B$1.66
LLYEli Lilly & Co.DBC$1174.61
JNJJohnson & JohnsonDCB$268.04
ABBVABBVIE INC.DCB$255.48
MRKMerck & Co., Inc.DCB$148.35
NVSNovartis AGCCC$153.81
AZNAstraZeneca PLCCBC$162.70
NVONovo-Nordisk A/SBCC$45.61
ABTAbbott LaboratoriesCCC$112.47
PFEPfizer Inc.CDB$27.96
VRTXVertex Pharmaceuticals IncDCB$541.69

About Alzamend Neuro, Inc. Common Stock

Alzamend Neuro is an early-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases and psychiatric disorders, with a focus on Alzheimer's disease. Its pipeline consists of AL001, a patented lithium-based ionic cocrystal technology, and AL002, a cell-based therapeutic vaccine designed to restore immune response against Alzheimer's.